📣 VC round data is live. Check it out!

Getinge Valuation Multiples

Discover Getinge's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Andon Health, Bausch + Lomb, Teleflex, Sysmex and more.

Getinge Overview

About Getinge

Getinge, headquartered in Gothenburg, Sweden, manufactures a wide range of products for use in acute care, surgical, and life sciences in the hospital, pharmaceutical, and research settings. The company reports in three segments: acute care therapies (52% of revenue), surgical workflows (35%), and life sciences (13%). Product areas include ventilators, surgical stents, life support systems, sterilizers, surgical tables, and sterile transfer systems. Getinge derives revenue from a broad geographic footprint, with the Americas accounting for 45% of sales, Europe, Middle East, and Africa 35%, and Asia-Pacific the remaining 25%.


Founded

1904

HQ

Sweden

Employees

11.8K

Financials (LTM)

Revenue: $4B
EBITDA: $718M

EV

$6B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Getinge Financials

Getinge reported last 12-month revenue of $4B and EBITDA of $718M.

In the same LTM period, Getinge generated $2B in gross profit, $718M in EBITDA, and $277M in net income.

Revenue (LTM)


Getinge P&L

In the most recent fiscal year, Getinge reported revenue of $4B and EBITDA of $718M.

Getinge is profitable as of last fiscal year, with gross margin of 45%, EBITDA margin of 18%, and net margin of 6%.

See analyst estimates for Getinge
LTMLast FY202320242025202620272028
Revenue$4B$4B$3B$4B$4B
Gross Profit$2B$2B$2B$2B$2B
Gross Margin49%45%46%46%48%
EBITDA$718M$718M$634M$570M$651M
EBITDA Margin19%18%19%15%17%
EBIT Margin12%12%13%11%13%
Net Profit$277M$256M$259M$176M$243M
Net Margin7%6%8%5%6%
Net Debt-$645M---

Financial data powered by Morningstar, Inc.

Getinge Stock Performance

Getinge has current market cap of $5B, and enterprise value of $6B.

Market Cap Evolution


Getinge's stock price is $19.93.

Getinge share price decreased by 3.8% in the last 30 days, and by 2.6% in the last year.

Getinge has an EPS (earnings per share) of $0.94.

See more trading valuation data for Getinge
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$6B$5B-3.0%-3.8%-3.3%-2.6%$0.94

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Getinge Valuation Multiples

Getinge trades at 1.6x EV/Revenue multiple, and 8.6x EV/EBITDA.

See NTM and 2027E valuation multiples for Getinge

EV / Revenue (LTM)


Getinge Financial Valuation Multiples

As of June 3, 2026, Getinge has market cap of $5B and EV of $6B.

Getinge has a P/E ratio of 19.6x.

LTMLast FY202320242025202620272028
EV/Revenue1.6x1.6x1.8x1.7x1.6x
EV/EBITDA8.6x8.6x9.7x10.8x9.5x
EV/EBIT13.7x12.9x13.9x15.6x12.9x
EV/Gross Profit3.3x3.5x4.0x3.6x3.5x
P/E19.6x21.2x20.9x30.8x22.4x
EV/FCF24.9x21.8x35.8x17.6x21.8x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Getinge Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Getinge Margins & Growth Rates

Getinge decreased revenue by 5% and EBITDA by 0% in the last fiscal year.

In the most recent fiscal year, Getinge reported gross margin of 45%, EBITDA margin of 18%, and net margin of 6%.

See estimated margins and future growth rates for Getinge

Getinge Margins

Last FY202420252026202720282029
Gross Margin45%46%48%49%
EBITDA Margin18%15%17%19%
EBIT Margin12%11%13%13%
Net Margin6%5%6%8%
FCF Margin7%9%8%8%

Getinge Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth(5%)9%1%(0%)
Gross Profit Growth3%11%3%3%
EBITDA Growth(0%)(10%)14%10%
EBIT Growth1%(11%)21%1%
Net Profit Growth19%(32%)38%26%
FCF Growth7%104%(19%)7%

Data powered by FactSet, Inc. and Morningstar, Inc.

Getinge Operational KPIs

Getinge's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.1M for the same period.

Getinge's Rule of 40 is 19% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Getinge's Rule of X is 19% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Getinge
LTMLast FY202320242025202620272028
Rule of 4017%19%---
Bessemer Rule of X16%19%---
Revenue per Employee-$0.3M---
Opex per Employee-$0.1M---
S&M Expenses to Revenue17%17%17%15%15%
G&A Expenses to Revenue13%13%14%12%12%
R&D Expenses to Revenue4%4%4%4%4%
Opex to Revenue-33%33%36%35%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Getinge Competitors

Getinge competitors include Andon Health, Bausch + Lomb, Teleflex, Sysmex, Snibe, Renishaw, Ypsomed, Convatec Group, Abbott India and Hamamatsu Photonics.

Most Getinge public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Andon Health25.2x-12.7x-
Bausch + Lomb2.0x1.9x11.4x10.7x
Teleflex4.0x3.7x13.0x13.1x
Sysmex1.7x1.7x7.2x8.6x
Snibe7.2x6.9x16.1x15.7x
Renishaw5.1x4.7x22.8x20.8x
Ypsomed6.4x6.4x14.3x14.6x
Convatec Group2.7x2.6x10.1x9.8x

This data is available for Pro users. Sign up to see all Getinge competitors and their valuation data.

Start Free Trial

Acquisitions by Getinge

Getinge has acquired 10 companies to date.

Last acquisition by Getinge was on April 7th 2026. Getinge acquired Pennamed for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Getinge

Pennamed
Paragonix Technologies
Healthmark Industries
High Purity New England
Description
Pennamed is a specialist distributor of endoscopic consumables and related medical supplies.
Paragonix Technologies is a Waltham, Massachusetts-based developer of organ preservation and transport systems for transplantation. The company manufactures SherpaPak devices for heart, lung, and kidney transport, maintaining organs at 4-8°C with clinical monitoring. Its products reduce ischemic time and improve graft survival rates, used in over 10,000 transplants since FDA clearance in 2016. Founded in 2010, Paragonix Technologies partners with centers like Cleveland Clinic and expands internationally to Europe.
Healthmark Industries is a manufacturer of products for surgical instrument reprocessing in healthcare facilities. The Fraser-based company develops cleaning validation tools, packaging solutions for sterilization, storage systems, and identification devices for emergency medical supplies. Its offerings include enzymatic cleaners, inspection brushes, and container management systems used in hospitals and surgery centers nationwide.
High Purity New England is a manufacturer and distributor of fluid handling and bioprocessing equipment for the life sciences industry. Based in Londonderry, New Hampshire, the company produces diaphragm pumps, flow sensors, single-use bioreactor assemblies, and chromatography columns. It supplies stainless steel and plastic pumps for pharmaceutical filling lines and biotech pilot plants, with flow rates from 0.1 to 100 liters per minute. High Purity New England serves clients in New England and nationwide, stocking over 5,000 SKUs for rapid delivery.
HQ CountryUnited KingdomUnited StatesUnited StatesUnited States
HQ City
Welton
Boston, MA
Detroit, MI
Providence, RI
Deal Date7 Apr 202622 Aug 202411 Oct 202331 May 2023
Valuationundisclosed$477M$320M$120M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Getinge acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Getinge

When was Getinge founded?Getinge was founded in 1904.
Where is Getinge headquartered?Getinge is headquartered in Sweden.
How many employees does Getinge have?As of today, Getinge has over 11K employees.
Who is the CEO of Getinge?Getinge's CEO is Mattias Perjos.
Is Getinge publicly listed?Yes, Getinge is a public company listed on Nasdaq Stockholm.
What is the stock symbol of Getinge?Getinge trades under GETI B ticker.
When did Getinge go public?Getinge went public in 1998.
Who are competitors of Getinge?Getinge main competitors include Andon Health, Bausch + Lomb, Teleflex, Sysmex, Snibe, Renishaw, Ypsomed, Convatec Group, Abbott India, Hamamatsu Photonics.
What is the current market cap of Getinge?Getinge's current market cap is $5B.
What is the current revenue of Getinge?Getinge's last 12 months revenue is $4B.
What is the current revenue growth of Getinge?Getinge revenue growth (NTM/LTM) is (1%).
What is the current EV/Revenue multiple of Getinge?Current revenue multiple of Getinge is 1.6x.
What is the current EBITDA of Getinge?Getinge's last 12 months EBITDA is $718M.
What is Getinge's EBITDA margin?Getinge's last 12 months EBITDA margin is 19%.
What is the current EV/EBITDA multiple of Getinge?Current EBITDA multiple of Getinge is 8.6x.
What is the current FCF of Getinge?Getinge's last 12 months FCF is $248M.
What is Getinge's FCF margin?Getinge's last 12 months FCF margin is 6%.
What is the current EV/FCF multiple of Getinge?Current FCF multiple of Getinge is 24.9x.
How many companies Getinge has acquired to date?As of June 2026, Getinge has acquired 10 companies.
What was the largest acquisition by Getinge?$477M acquisition of Paragonix Technologies on 22nd August 2024 was the largest M&A Getinge has done to date.
What companies Getinge acquired?Getinge acquired Paragonix Technologies, Healthmark Industries, High Purity New England, Applikon Biotechnology, Tails Clinical, Fluoptics, Quadralene, Cetrea, c.a.r.u.s, and Pennamed.
In how many companies Getinge has invested to date?Getinge hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Getinge

Lists including Getinge

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial